Inzucchi, Silvio E <br/><br/>
Are the cardiovascular and kidney benefits of empagliflozin influenced by baseline glucose-lowering therapy?  [electronic resource] 

 -  Diabetes, obesity & metabolism  04 2020 
 - 631-639 p.  digital 
<br/><br/> Publication Type: Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1463-1326 
<br/><br/><label>Standard No.: </label>10.1111/dom.13938  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Benzhydryl Compounds--therapeutic use<br/>Cardiovascular Diseases--epidemiology<br/>Diabetes Mellitus, Type 2--drug therapy<br/>Glucose<br/>Glucosides--therapeutic use<br/>Humans<br/>Hypoglycemic Agents--therapeutic use<br/>Kidney